Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.30 |
| ▸ | F10 | P00742 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL584019 | 1.00 | KDM4E (0.31) | KDM4EL3MBTL1ALDH1A1LMNAPOLB | |
| SCHEMBL584817 | 1.00 | KDM4E (0.31) | KDM4EL3MBTL1ALDH1A1LMNAPOLB | |
| SCHEMBL583823 | 0.93 | KDM4E (0.36) | KDM4EL3MBTL1ALDH1A1POLBTDP1 | |
| SCHEMBL2524072 | 0.93 | KDM4E (0.36) | KDM4EL3MBTL1ALDH1A1POLBTDP1 | |
| SCHEMBL584016 | 0.93 | KDM4E (0.36) | KDM4EL3MBTL1ALDH1A1POLBTDP1 | |
| SCHEMBL584990 | 0.88 | CALML3 (0.34) | KDM4EALDH1A1LMNAPOLBNPSR1 | |
| SCHEMBL2531151 | 0.88 | CALML3 (0.34) | KDM4EALDH1A1LMNAPOLBNPSR1 | |
| SCHEMBL2526650 | 0.87 | STAT3 (0.33) | KDM4EALDH1A1LMNAPOLBNPSR1 | |
| SCHEMBL2841950 | 0.86 | TOP2B (0.35) | KDM4EALDH1A1LMNAPOLBNPSR1 | |
| SCHEMBL3063470 | 0.86 | TOP2B (0.35) | KDM4EALDH1A1LMNAPOLBNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2102217-B1 | 4- (2-OXO-OXAZOLIDIN-3YL)-PHENOXYMETHYLE DERIVATIVEAS AS ANTIBACTERIALS | ACTELION PHARMACEUTICALS LTD (CH) | 2012-02-15 | — | — | EP | disclosed |
| US-8039466-B2 | 5-hydroxymethyl-oxazolidin-2-one antibacterials | ACTELION PHARMACEUTICAL LTD. (CH) | 2011-10-18 | — | — | US | disclosed |
| US-20100069376-A1 | 5-HYDROXYMETHYL-OXAZOLIDIN-2-ONE ANTIBACTERIALS | ACTELION PHARMACEUTICALS, LTD. (CH) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069376-A1 | 5-HYDROXYMETHYL-OXAZOLIDIN-2-ONE ANTIBACTERIALS | OGFOD1, ODC1, OXGR1 | KDM4E 1273/4885L3MBTL1 460/4885ALDH1A1 698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.